These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

495 related articles for article (PubMed ID: 1955518)

  • 1. Combined administration of a gonadotropin-releasing hormone antagonist and testosterone in men induces reversible azoospermia without loss of libido.
    Pavlou SN; Brewer K; Farley MG; Lindner J; Bastias MC; Rogers BJ; Swift LL; Rivier JE; Vale WW; Conn PM
    J Clin Endocrinol Metab; 1991 Dec; 73(6):1360-9. PubMed ID: 1955518
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction of azoospermia in normal men with combined Nal-Glu gonadotropin-releasing hormone antagonist and testosterone enanthate.
    Tom L; Bhasin S; Salameh W; Steiner B; Peterson M; Sokol RZ; Rivier J; Vale W; Swerdloff RS
    J Clin Endocrinol Metab; 1992 Aug; 75(2):476-83. PubMed ID: 1639948
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of a gonadotropin releasing-hormone antagonist plus testosterone (T) versus T alone as potential male contraceptive regimens.
    Bagatell CJ; Matsumoto AM; Christensen RB; Rivier JE; Bremner WJ
    J Clin Endocrinol Metab; 1993 Aug; 77(2):427-32. PubMed ID: 8345047
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Suppression of spermatogenesis in man induced by Nal-Glu gonadotropin releasing hormone antagonist and testosterone enanthate (TE) is maintained by TE alone.
    Swerdloff RS; Bagatell CJ; Wang C; Anawalt BD; Berman N; Steiner B; Bremner WJ
    J Clin Endocrinol Metab; 1998 Oct; 83(10):3527-33. PubMed ID: 9768659
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison between testosterone enanthate-induced azoospermia and oligozoospermia in a male contraceptive study. I: Plasma luteinizing hormone, follicle stimulating hormone, testosterone, estradiol, and inhibin concentrations.
    Wallace EM; Gow SM; Wu FC
    J Clin Endocrinol Metab; 1993 Jul; 77(1):290-3. PubMed ID: 8325955
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Depot gonadotropin-releasing hormone agonist blunts the androgen-induced suppression of spermatogenesis in a clinical trial of male contraception.
    Behre HM; Nashan D; Hubert W; Nieschlag E
    J Clin Endocrinol Metab; 1992 Jan; 74(1):84-90. PubMed ID: 1727833
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparison of the suppressive effects of testosterone and a potent new gonadotropin-releasing hormone antagonist on gonadotropin and inhibin levels in normal men.
    Bagatell CJ; McLachlan RI; de Kretser DM; Burger HG; Vale WW; Rivier JE; Bremner WJ
    J Clin Endocrinol Metab; 1989 Jul; 69(1):43-8. PubMed ID: 2499592
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of chronic testosterone administration in normal men: safety and efficacy of high dosage testosterone and parallel dose-dependent suppression of luteinizing hormone, follicle-stimulating hormone, and sperm production.
    Matsumoto AM
    J Clin Endocrinol Metab; 1990 Jan; 70(1):282-7. PubMed ID: 2104626
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gonadotropin-releasing hormone antagonist plus testosterone: a potential male contraceptive.
    Bremner WJ; Bagatell CJ; Steiner RA
    J Clin Endocrinol Metab; 1991 Sep; 73(3):465-9. PubMed ID: 1874925
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sperm motion parameters after suppression of spermatogenesis with a gonadotropin-releasing hormone antagonist plus testosterone supplementation.
    Bastias MC; Kamijo H; Pavlou SN
    Fertil Steril; 1993 Jun; 59(6):1261-5. PubMed ID: 8495775
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Establishing the minimum effective dose and additive effects of depot progestin in suppression of human spermatogenesis by a testosterone depot.
    Handelsman DJ; Conway AJ; Howe CJ; Turner L; Mackey MA
    J Clin Endocrinol Metab; 1996 Nov; 81(11):4113-21. PubMed ID: 8923869
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hormonal effects of gonadotropin-releasing hormone (GnRH) agonist in the human male. III. Effects of long term combined treatment with GnRH agonist and androgen.
    Bhasin S; Heber D; Steiner BS; Handelsman DJ; Swerdloff RS
    J Clin Endocrinol Metab; 1985 May; 60(5):998-1003. PubMed ID: 3920237
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined administration of levonorgestrel and testosterone induces more rapid and effective suppression of spermatogenesis than testosterone alone: a promising male contraceptive approach.
    Bebb RA; Anawalt BD; Christensen RB; Paulsen CA; Bremner WJ; Matsumoto AM
    J Clin Endocrinol Metab; 1996 Feb; 81(2):757-62. PubMed ID: 8636300
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low dose of cyproterone acetate and testosterone enanthate for contraception in men.
    Meriggiola MC; Bremner WJ; Costantino A; Di Cintio G; Flamigni C
    Hum Reprod; 1998 May; 13(5):1225-9. PubMed ID: 9647551
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potential of testosterone buciclate for male contraception: endocrine differences between responders and nonresponders.
    Behre HM; Baus S; Kliesch S; Keck C; Simoni M; Nieschlag E
    J Clin Endocrinol Metab; 1995 Aug; 80(8):2394-403. PubMed ID: 7543113
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heterogeneity of sperm density profiles following 16-week therapy with continuous infusion of high-dose LHRH analog plus testosterone.
    Pavlou SN; Interlandi JW; Wakefield G; Rivier J; Vale W; Rabin D
    J Androl; 1986; 7(4):228-33. PubMed ID: 3528106
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mode of suppression of pituitary and gonadal function after acute or prolonged administration of a luteinizing hormone-releasing hormone antagonist in normal men.
    Pavlou SN; Wakefield G; Schlechter NL; Lindner J; Souza KH; Kamilaris TC; Konidaris S; Rivier JE; Vale WW; Toglia M
    J Clin Endocrinol Metab; 1989 Feb; 68(2):446-54. PubMed ID: 2537334
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Suppression of human spermatogenesis by testosterone implants.
    Handelsman DJ; Conway AJ; Boylan LM
    J Clin Endocrinol Metab; 1992 Nov; 75(5):1326-32. PubMed ID: 1430094
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hormonal effects of gonadotropin-releasing hormone (GnRH) agonist in men: effects of long term treatment with GnRH agonist infusion and androgen.
    Bhasin S; Yuan QX; Steiner BS; Swerdloff RS
    J Clin Endocrinol Metab; 1987 Sep; 65(3):568-74. PubMed ID: 3114307
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Persistence of concordant luteinizing hormone (LH), testosterone, and alpha-subunit pulses after LH-releasing hormone antagonist administration in normal men.
    Pavlou SN; Veldhuis JD; Lindner J; Souza KH; Urban RJ; Rivier JE; Vale WW; Stallard DJ
    J Clin Endocrinol Metab; 1990 May; 70(5):1472-8. PubMed ID: 2110578
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.